Core Points - MediPharm Labs Corp. has successfully dismissed a $50 million defamation claim against its CEO and Chairman by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][2][3] - The Ontario Superior Court found that the claims were baseless and that the plaintiffs failed to provide evidence of harm caused by the statements made in a letter related to a proxy contest [3] - The company has also reported unauthorized press releases related to Apollo that were disseminated without its consent [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada and internationally [7]

Core Viewpoint - MediPharm Labs Corp. has successfully dismissed a defamation claim against its CEO and Chairman, reinforcing its legal standing and credibility in the market [1][2][3]. Legal Developments - The Superior Court of Justice in Ontario dismissed a $50 million defamation claim against CEO David Pidduck and Chairman Chris Taves, which was initiated by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][3] - The court's decision followed a previous dismissal of a related conflict of interest claim against the company's litigation counsel [2]. - The court found that the plaintiffs failed to provide evidence of harm caused by the April 29 letter, which was deemed typical of legal correspondence in such circumstances [3]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [6]. - In 2023, MediPharm expanded its market reach by acquiring VIVO Cannabis Inc., enhancing its presence in Canada, Australia, and Germany [7].

As filed with the U.S. Securities and Exchange Commission on October 16, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aeon Acquisition I Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Cayman Islands 6770 N/A (Primary Standard Industrial Classification Code Number) | Mitchell S. Nussbaum | Jose Santos | Brandon J. ...

Core Viewpoint - The merger between MBody AI and Check-Cap aims to create a combined company focused on embodied AI for the autonomous workforce, with Check-Cap continuing its legacy research and development activities [1][3]. Company Overview - MBody AI is a leading AI company specializing in embodied AI, with a market forecast to reach $40 trillion by 2050, contributing over $16 trillion in additional value to global equity markets [2]. - The company is developing a proprietary AI stack designed to power intelligent systems that can learn, adapt, and optimize in real time, with initial applications in hospitality and plans for expansion into warehousing, office management, and healthcare [2]. Merger Details - The merger will result in MBody AI equityholders owning 90% and Check-Cap equityholders owning 10% of the combined company on a fully diluted basis [4]. - The combined entity will be named "MBody AI Ltd." and will retain Check-Cap's legacy assets, including patents and proprietary medical equipment [3]. Strategic Synergies - The merger is expected to create synergies with Check-Cap's Ghost Kitchen franchise rights in New Jersey, leveraging shared technology and operational resources [5]. Approval Process - The merger has been approved by the boards of both companies and is pending approval from Check-Cap shareholders at the Annual General Meeting scheduled for October 17, 2025 [6]. Financial Compliance - Check-Cap received a notification from Nasdaq regarding non-compliance with listing rules, requiring a plan to regain compliance by October 20, 2025, which the merger and related financing are expected to enhance [7][8].

Core Viewpoint - MediPharm Labs Corp. responds to a misleading press release from Apollo Technology Capital Corporation regarding the results of its annual and special meeting of shareholders, emphasizing that the meeting has not yet occurred and results are not available [1][2]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products, utilizing a Good Manufacturing Practices certified facility [3]. - The company has invested in a research-driven team and state-of-the-art technology to deliver precision-dosed cannabis products to both domestic and international medical markets [3]. Regulatory Milestones - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, making it the only company in North America with a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids [4]. - This GMP license is a crucial step towards the company's foreign drug manufacturing site registration with the US FDA [4]. Recent Acquisitions - In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded its reach to medical patients in Canada and internationally through various platforms and clinics [5]. - The acquisition included Harvest Medical Clinics in Canada, which provides consultations for medical cannabis education and prescriptions [5]. Compliance and Operations - The company operates in compliance with all applicable laws in the countries where it conducts business [6].

Core Viewpoint - MediPharm Labs Corp. has successfully dismissed a legal application from Apollo Technology Capital Corporation and Nobul Technologies Inc. regarding the appointment of a third-party independent chair for the upcoming shareholder meeting [1][2][3] Legal Proceedings - The Superior Court of Justice in Ontario dismissed the application that sought to appoint an independent chair for the Annual and Special Meeting of Shareholders scheduled for June 16, 2025 [1][2] - The Court found no evidence that MediPharm's proposed meeting chair would act unfairly, thus negating the need for a third-party chair [3] Allegations and Conduct - Apollo's principal, Mr. Regan McGee, made serious allegations against MediPharm, including securities fraud and breach of fiduciary duty, and threatened to release damaging statements [3] - Mr. McGee initiated a lawsuit claiming $50 million in damages against MediPharm and its senior officers, but later withdrew certain claims and agreed to terms that included a declaration of no conflict of interest for the Company's legal counsel [3] Shareholder Voting Guidance - MediPharm encourages shareholders to vote using only the GREEN proxy or voting instruction card to support the Board's nominees and resolutions [4][5] - Shareholders are advised to contact their brokers to obtain their control numbers for voting and to disregard any communications from dissident parties [6] Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis products [7][8] - The company holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [9] - In 2023, MediPharm expanded its operations through the acquisition of VIVO Cannabis Inc., enhancing its reach in the medical cannabis market [10]

Core Viewpoint - Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has presented a plan aimed at revitalizing the company and enhancing shareholder value [1][6]. Shareholder Engagement - Shareholders are encouraged to vote for Apollo Capital's six director nominees using the "Gold Card" and to disregard MediPharm's "Green Card" [2][3]. - The communication emphasizes the urgency for shareholders to act in order to protect their investments [2][3]. Ownership and Influence - Apollo Capital, through its subsidiary Nobul Technologies Inc., owns approximately 3% of MediPharm's common shares, totaling 12,491,500 shares [4][6]. - The company is actively seeking to influence the board of directors through its proxy solicitation efforts [11]. Action Plan - Apollo Capital has outlined a commitment to execute an aggressive action plan aimed at increasing MediPharm's share price by over 10 times and preventing insolvency [6]. - The plan includes measures to address excessive executive compensation and rectify three years of value-destructive actions [6]. Legal and Regulatory Compliance - Apollo Capital has filed an amended dissident information circular in compliance with Canadian corporate and securities laws, detailing their director nominees and the rationale behind their actions [5][7]. - Shareholders are advised to read the amended circular carefully as it contains crucial information regarding the upcoming annual meeting [8].

Core Viewpoint - Apollo Capital and Pat McCutcheon emphasize the urgent need for change at MediPharm Lab Corp, advocating for a complete turnover at the board level to restore value for shareholders after years of mismanagement and declining share prices [1][2][5]. Group 1: Management and Governance Issues - MediPharm's share price has significantly collapsed over the past three years, while senior management has received over $10 million in compensation, raising concerns about governance and accountability [2][4]. - The current management has deviated from MediPharm's founding vision by entering the recreational cannabis market and engaging in dilutive mergers and acquisitions, which has not aligned with shareholder interests [2][3]. Group 2: Proposed Changes and Support - Apollo Capital proposes a new board of directors with relevant experience in medical cannabis and turnaround strategies, led by Regan McGee, to drive the company's stock price higher [3][4]. - Shareholders are urged to support Apollo's director nominees by voting the GOLD CARD in the upcoming AGM, as this aligns with the goal of enhancing shareholder value [4][8]. Group 3: Shareholder Engagement - Apollo Capital's business model focuses on investing in poorly managed companies and working with shareholders to secure votes for new governance that prioritizes share value growth [4][5]. - The strategic five-pillar plan for MediPharm has been made available to shareholders, outlining the steps needed to transform the company into a leading player in the medical cannabis sector [7].

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to be cautious regarding the election of three Dissident Nominees associated with Apollo Technology Capital Corporation, citing concerns over their past involvement with Check-Cap Ltd. and its governance issues [1][2][18]. Summary of Recent Events at Check-Cap - Check-Cap has faced significant governance challenges, including poor transparency, high turnover, and questionable cash resource allocation, leading to a decline in shareholder value [3][6]. - A notable incident involved Check-Cap transferring millions of dollars to Apollo and its subsidiaries, which raises concerns about the motives of the Dissident Nominees [4][11]. - The Check-Cap Board approved a $6 million loan to Nobul and transferred $11 million to a segregated account for Nobul's growth initiatives, despite no formal business combination being completed [8][9]. Connections to the Dissident Nominees - Three of the six Dissident Nominees for MediPharm's Board have been directly involved in Check-Cap's governance issues, raising questions about their qualifications to lead another public company [11][14]. - The involvement of these individuals in Check-Cap's tumultuous history suggests a potential risk for MediPharm shareholders [12][18]. Shareholder Voting Assistance - MediPharm encourages shareholders to vote using the GREEN proxy in support of the Company's nominees, emphasizing the importance of disregarding communications from the Dissident Nominees [19][20]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis products and has a GMP license from Health Canada, positioning it as a leader in the cannabinoid sector [21][23]. - The Company expanded its reach through the acquisition of VIVO Cannabis Inc., enhancing its presence in the medical cannabis market [24].

Core Viewpoint - MediPharm Labs Corp. is addressing concerns regarding Regan McGee, a dissident shareholder and CEO of Apollo Technology Capital Corporation, who is seeking to elect himself and five other directors to the MediPharm board at the upcoming shareholder meeting [1][2]. Group 1: Allegations Against Regan McGee - Allegations have been made against Mr. McGee regarding his business conduct, including claims of misusing company resources and setting his own compensation through a conflicted process [3][6]. - Former colleagues of Mr. McGee have accused him of misrepresenting the nature of Nobul Technologies Inc.'s business, claiming it was a technology innovator when it primarily operated as a traditional real estate brokerage [7][8]. - There are serious allegations that Mr. McGee and his associates misled investors about Nobul's financial health and used funds for personal enrichment rather than business expansion [12][14]. Group 2: Legal Proceedings - Multiple litigation cases involving Nobul Technologies Inc. and Mr. McGee have been cited, including claims of fraudulent misrepresentation and breach of fiduciary duty [26][30]. - The allegations in these cases include claims that Mr. McGee used Nobul as a façade to deceive investors, leading to significant financial losses for those who invested based on misleading information [13][14]. - The legal actions also highlight governance issues, with former directors expressing concerns about Mr. McGee's control over the company and the lack of transparency in operations [10][11]. Group 3: MediPharm's Position - MediPharm urges shareholders to support its nominees and resolutions by voting with the GREEN proxy, emphasizing the importance of governance and the qualifications of its board members [16][17]. - The company has communicated that shareholders should disregard any outreach from the dissident group and focus on the information provided by MediPharm [18].